CIMA Sciences, LLC is a biotechnology company focused in bringing to the scientific community and US population the best non-invasive diagnostic technology for high prevalence disease.
Our Story
Founded in 2022 with headquarters in San Antonio, Texas, CIMA Sciences is dedicated to advancing non-invasive diagnostic solutions for widespread medical conditions. With a focus on liver and cardiovascular health, our mission is to equip healthcare providers and researchers with innovative tools that enable earlier detection, improved patient outcomes, and more efficient clinical decision-making.
By combining cutting-edge biotechnology with rigorous scientific research, CIMA Sciences develops diagnostics that are both clinically meaningful and easy to implement. Our flagship test, OWLiver®, exemplifies this approach—providing a fast, reliable, and non-invasive method to assess all stages of MASLD. Through innovation and collaboration, we aim to close critical gaps in early disease detection and support a higher standard of care across the healthcare system.
Our Team
Behind every innovation at CIMA Sciences is a team committed to improving the lives of patients. Our leaders bring extensive experience in medicine, research, and healthcare commercialization, working together to advance non-invasive diagnostics that enable earlier, more accurate detection of liver disease.
Frank Amato
President and Chief Executive Officer
Francis “Frank” Amato is President and Chief Executive Officer of CIMA Sciences and a seasoned life sciences executive. He previously served as CEO of Nasdaq-listed electroCore and as Group Vice President at Merck, where he led multi-billion-dollar business divisions and large-scale global integrations. A former U.S. Army airborne infantry field medic, Frank brings a distinctive perspective on disciplined leadership, operational excellence, and advancing healthcare innovation. He holds degrees from St. John’s University and Pepperdine University and resides in Charleston, South Carolina.
Mazen Noureddin, MD, MHSc
Chief Medical Officer
Dr. Mazen Noureddin is Chief Medical Officer of CIMA Sciences and an internationally recognized leader in Steatotic Liver Disease (SLD), including SLD-related cirrhosis. A Professor of Medicine at Houston Methodist Hospital, he has authored more than 320 peer-reviewed publications and has served as a leader or investigator on more than 80 clinical trials. His expertise in non-invasive diagnostics, biomarkers, and therapeutic development helps guide CIMA Sciences’ scientific and clinical strategy. Dr. Noureddin has been involved with CIMA Sciences since the early development of OWLiver, helping shape its scientific foundation and clinical validation.
Sean Purdy
Vice President of Sales
Sean Purdy is Vice President of Sales at CIMA Sciences, bringing more than 20 years of pharmaceutical and life sciences commercial leadership experience. He has a proven track record of building high-performing sales organizations, developing commercial strategies, and driving growth in competitive healthcare markets. At CIMA Sciences, Sean leads the company’s commercial efforts to expand adoption of OWLiver and strengthen partnerships with healthcare providers across the country.
Partnership With Rubió Metabolomics
The OWLiver® Test was originally developed by Rubió Metabolomics following extensive metabolomics analysis and preclinical research. The development and validation of the OWLiver® test was based on a multicenter and multiethnic study, that included patients with a body mass index exceeding 25 kg/m² and various degrees of type 2 diabetes mellitus, including non-diabetics, controlled diabetics, and diabetics with poor glycemic control.
The OWLiver® Test is a CE-marked in vitro diagnostic medical device, complying with Directive 98/79/EC. It is based on a retrospective study in which patients had previously been diagnosed using the gold standard for this disease, liver biopsy.
Rubió Metabolomics is a global provider of metabolomics services to the pharmaceutical industry, primarily focused on supporting clinical trials in liver diseases and other prevalent human diseases. It also focuses on research in indications where metabolomics plays a key role, including drug therapy monitoring and biomarker discovery.
Advancing Non-Invasive Diagnostics.
Order OWLiver® Test
OWLiver® is a non-invasive blood test to assess MASLD. It analyzes a panel of biomarkers through metabolomics methodology.